

36° Congresso Nazionale della Società Italiana di Farmacologia

Scientific Programme

	Auditorium	Sala 500	Madrid	Londra	Copenhagen	Dublino	Lisbona
October 23, 2013							
11.00	Registrazione						
15.00	NS23 SIF - SSFA Symposium: Clinical Research in Italy: how to compete?	MS4 Innovation and technology for a competitive and sustainable health care system	NS13 Nanomedicines for cancer therapy	C2 Oral Communications Stroke and Neuroinflammation		MS10 Rifaximin, an Ever Green Antibiotic: New Insights and New Therapeutic Applications (15.00-16.30)	
16.00							
17.00	Welcome Ceremony						
18.00	Lectio Magistralis Pasinelli						

36° Congresso Nazionale della Società Italiana di Farmacologia

	Auditorium	Sala 500	Madrid	Londra	Copenhagen	Dublino	Lisbona
October 24, 2013							
8.30	C5 Oral Communications Pharmaco- epidemiology and Pharmacovigilance	NS25 Inflammation and vulnerability to neuropsychiatric disorders: molecular mechanisms and clinical outcomes	NS16 Neurodegenerative diseases and brain injury: from cellular and molecular mechanisms to new neuroprotective strategies		C3 Oral Communications Personalized Medicine	C4 Oral Communications Inflammations Pharmacology	C6 Oral Communications Metabolism Pharmacology
9.30				L16 Omega-3 fatty acids in cardiovascular prevention: how and when?			
10.00				L3 Serelaxin: beyond the validation for AHF patient			
10.30	Coffee break						
11.00		NS1 SIF-SINPF-SIP- SITOX Neurobiological and Clinical Continuum Between Psychopathology on Abuse of Substances	S1 Pharmacological innovation in onco- hematology	S6 Pharmacological management of patients at high cardiovascular risk.	NS5 Aspetti farmacologi, clinici e regolatori delle Tossine Botuliniche	L20 Innovation in the treatment of IBD	
11.30	S5 Innovation beyond biotechnological drugs: the role of small molecules as target therapy						
12.00						S4 Adherence and economic sustainability in cardiovascular treatment	
12.30							
13.00		Pipeline lunch					Assemblea Sezione di Farmacologia Clinica
14.00	Lectio Magistralis Marquet						
15.00	L1 Nuovi approcci per la somministrazione di anticorpi monoclonali	SSS1 SIF-SISA Symposium: The challenge of innovation in cardiovascular medicine between the unmet needs and the sustainability of the healthcare system	NS4 Taking rational decisions in a world of uncertainty: how to use pharmaco- economics for reimbursement of new drugs	MS6 Alzheimer disease: today's update	MS8 Stato attuale e prospettive della farmacologia clinica dell'età pediatrica	L21 New treatments of Clostridium difficile infections	
15.30							
16.00	MS5 The innovation of targeted therapy in the treatment of Hodgkin Lymphoma and sALCL			L15 Thermo-TRP inhibition: novel strategies to treat pain and more		MS9 Quality of equivalent (generic) drugs	

36° Congresso Nazionale della Società Italiana di Farmacologia

October 24, 2013							
17.00	NS20 Emerging role of the endocannabinoid signaling in neuropsychiatric disorders	C17 Oral Communications Pharmacology of Pain	NS9 Clinical pharmacology and public health	NS18 Alzheimer disease: identification of novel targets and therapeutic tools	NS3 The need of Mitochondrial Pharmacology	NS7 Enzymes regulating the intra- and extra-cellular activities of purines and their antineoplastic analogues	
19.00	Assemblea Collegio Nazionale Farmacologi Universitari						
19.30 - 21.00	P1 Poster Session						

36° Congresso Nazionale della Società Italiana di Farmacologia

	Auditorium	Sala 500	Madrid	Londra	Copenhagen	Dublino	Lisbona
October 25, 2013							
8.30	C10 Oral Communications Cardiovascular Pharmacology 1	NS14 New research on neurodegeneration: time to translate it to clinic?	NS21 Stress as a risk factor for neuropsychiatric disorders. Cognitive and metabolic aspects		NS17 Nuovi bersagli farmacologici nella malattia di Parkinson	NS6 Insights in purinergic signalling in normal and pathological conditions of different cells and tissues	NS22 Cardiac Stem Cells Ten Years Later: future developments
10.00				L23 Rivaroxaban: dalle caratteristiche farmacologiche alle evidenze cliniche nella fibrillazione atriale e oltre			
10.30	Coffee break						
11.00	C18 Oral Communications Neuropsycho- pharmacology	L9 Nuove soluzioni terapeutiche nell'ambito dell'antibioticoterapia: una valutazione degli impatti farmacoeconomici	L14 Clinical, social and economic evaluation of hypoglycemia in relation to the drug treatment	L4 Preclinical development and clinical implications of mTOR inhibition in solid oncology	MS11 Before, during and after drugs: stay healthy while saving	L17 Functional Gastrointestinal Disorders: Role of Guanylate Cyclase C agonist	NS10 Rare diseases: from gene to therapy: few bricks in the wall
11.30		MS3 Innovation and sustainability in a time of financial crisis	L22 Ivabradine: from pharmacological innovation to clinical benefits in heart failure	L2 Pharmacological innovation in the treatment of skin cancer: from melanoma to basal cell carcinoma		L19 New treatments for COPD: pharmacological profile of Acridinium Bromide	
12.00				L7 New immunological pathways: the role of IL-17 in psoriasis	C16 Oral Communications Pharmacology of the Respiratory Function		
12.30			L10 Clinical practice and antidepressive drugs	L13 Tumore alla prostata: meccanismi di azione dei nuovi farmaci		L12 Alginate containing formulations for the management of gastro-esophageal reflux	
13.00	Lunch						

36° Congresso Nazionale della Società Italiana di Farmacologia

October 25, 2013							
13.30	P2 Poster session (area poster)						
15.00	L6 The pharmacological rationale of maximization of bronchodilation in COPD	MS7 Adherence to therapy and sustainability: a new paradigm for the future	S2 Update in pharmacological therapy of T2 Diabetes Mellitus	L11 Analogs of insulin and relative clinical practice: which differences?	C8 Oral Communications Neurogenesis	C11 Oral Communications Cardiovascular Pharmacology 2	
15.30	C20 Oral Communications Gender Pharmacology						
16.00	MS2 Gender medicine. Increasing appropriateness and sustainability through a sex-oriented approach	NS27 SIF-EPHAR Symposium: New paths for the treatment of alcohol addiction		L18 Role of iron in the treatment of anemia in chronic kidney disease			
17.00 - 19.00	Assemblea Generale della SIF						

36° Congresso Nazionale della Società Italiana di Farmacologia

	Auditorium	Sala 500	Madrid	Londra	Copenhagen	Dublino	Lisbona
October 26, 2013							
8.30	C19 Oral Communications Drugs of Abuse	C7 Oral Communications Alzheimer Pharmacology	NS24 Brain development and synaptic organization: regulation by intellectual disability genes and immune molecules	C12 Oral Communications Cardiovascular Pharmacology 3	C1 Oral Communications Pharmacognosy	C14 Oral Communications Receptors and Transduction Signal Mechanisms	C13 Oral Communications Antineoplastic Drugs
10.30	Coffee break						
11.00	C15 Oral Communications Neuropharmacology	MS1 A new drug, today on the market... do we really know it?	NS19 Fenotipizzazione della broncopneumo- patia cronica ostruttiva e terapia farmacologica personalizzata	L5 Multiple Sclerosis: Mechanism of action of the new oral DMDs	NS15 SIF-SIPHAR Symposium: Herbal products in research and practice: between lights and shadows	C9 Oral Communications Pharmacology of the Digestive Apparatus	NS28 SIF/EBRA Joint Symposium: The use of animals for scientific purposes: which implications for Italian research?
11.30							
12.00		NS26 Simposio SIF- AIOM: La farmacogenetica come strumento di personalizzazione della terapia antitumorale					
12.30							
13.00	Poster Awards						